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Retinopathy of prematurity (ROP) is an important cause of childhood 
blindness.[1] In the past, two epidemics occurred: the first when oxygen 
supplementation was used in an uncontrolled fashion in the 1950s, 
and the second when advances in paediatric care resulted in improved 
survival rates of extremely low-birth-weight babies in the 1970s. Strict 
oxygen administration and ROP screening with early intervention have 
since markedly reduced the likelihood of a poor visual outcome.[2,3]
Middle-income countries that have infant mortality rates of 
~50/100  000 population per annum are currently experiencing the 
so-called ‘third epidemic’ of ROP as a result of improved survival rates 
coupled with poor oxygen control and poorly established screening 
policies.[1] South Africa (SA), with shortages of human resources and 
material resources, is at risk of developing this epidemic.[4]
ROP screening has not been the norm in many SA state hospitals, 
but a national ROP screening protocol was published in 2013.[4,5] ROP 
screening is therefore a relatively new practice in many hospitals in SA.
We describe the challenges we faced and the successes we achieved 
with the development of a new ROP clinic at Dora Nginza Hospital 
in Port Elizabeth, SA.
Methods
Clinical management from the Port Elizabeth Hospital Complex 
supported the study, and ethical approval was obtained through the Walter 
Sisulu University Research Ethics Committee (Protocol No. 043/15).
A retrospective case folder review was conducted over the 6-year 
period 1 January 2009 - 31 December 2014 on all infants screened for 
ROP. During this period, ROP screening was managed according to 
the following guidelines:
The criteria for ROP screening during the 6-year period were: 
(i)  birth weight (BW) <1 501 g; (ii) gestational age <32 weeks; and 
(iii) BW 1 501 - 2 000 g if an unstable clinical course was reported.
The classification of disease severity was based on the revised 
International Classification of Retinopathy of Prematurity (ICROP) [6] 
definitions. These include stage (1 - 5), zone (I - III), ‘plus’ disease 
status (absent, pre-plus or plus), and extent (clock hours). Aggressive 
posterior ROP (AP-ROP) is a rapidly progressive condition with 
prominent plus disease in a posterior location and minimal 
proliferative changes (Fig. 1).
The threshold for intervention was based on the Early Treatment 
for Retinopathy of Prematurity (ETROP)[2] definitions. Type 1 ROP 
(T1ROP), defined as the presence of plus disease or stage 3 in zone I 
with no plus disease, was the indication for intervention. Type 2 ROP 
(T2ROP) was defined as zone I, stage 1 or 2 with no plus disease or 
zone II, stage 3 with no plus disease. These patients were observed.
Screening failures were defined as the presence of stage 4 or 
5 ROP because of the poor prognosis in these cases. A successful 
screening programme should detect and treat patients before they 
develop these late stages of ROP.
The final assessment would then place the screened infant into 
one of three categories:
• No ROP if the retina was fully vascularised or if normal 
vascularisation was noted in zone III with no signs of ROP
• ROP present:
• T1 ROP
• T2 and earlier ROP
• Screening failure if stage 4 or 5 present.
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Conclusions. Better management of ROP can be achieved through adequate provision of healthcare professionals and material resources 
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results in a more efficient screening programme.
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Treatment of T1ROP was laser photo-
coagulation of the avascular retina according 
to the ETROP guidelines.[2] From 2013 
onwards intravitreal bevacizumab (Avastin; 
Genentech) was used in cases of zone I 
disease according to the findings of the 
Bevacizumab Eliminates the Angiogenic 
Threat of Retinopathy of Prematurity 
(BEAT-ROP) study.[7] T2 and earlier cases 
of ROP were monitored according to the 
suggested schedule in the SA guidelines.[5]
Data collection
Data from patient folders were collected on:
• Number of new infants screened and 
number of follow-up examinations 
performed
• ROP screening status (recorded as either 
‘on time’ if between 5 and 6 weeks or ‘late’ 
if after 6 weeks)
• Number of cases of ROP detected
• Clinical findings and trends. Following 
classification of ROP, cases were divided 
into: (i) T1ROP cases needing intervention; 
(ii) T2 and earlier ROP needing observation; 
and (iii) screening failures
• Management of T1ROP: indirect laser 
photocoagulation or intravitreal beva-
cizumab injections
• Additional ophthalmological problems 
found incidentally during ROP screening
• Complications encountered during 
screening
• The impact of other events and inter-
ventions related to the prevention of ROP 
and screening for ROP.
General interventions implemented 
during the study period
Screening facilities. In 2009 and 2010, the 
facilities for screening were inadequate. 
The site was separate from the neonatal 
unit and awareness of screening was low, 
as reflected by the low number of infants 
screened. In 2011 a new neonatal unit was 
built with a dedicated ROP screening room 
and incubator, and this helped to heighten 
awareness of the service.
Health professional resources and fre­
quency of screening clinics. No ophthal-
mologists were based at the hospital, and the 
service had to be provided by the eye depart-
ment at Port Elizabeth Provincial Hospital. In 
2009 there were two ophthalmologists, in 2011 
three ophthalmologists, and from November 
2012 four ophthalmologists. The increase in 
the number of ophthalmologists enabled us 
to increase the frequency of visits from every 
3 weeks in 2009 to every 2 weeks in 2011 and 
weekly by 2013.
Education of staff. In 2012, ROP teaching 
became integrated into the paediatric academic 
programme. These sessions focused on the 
management of oxygen supplementation in 
infants and appropriate referral of infants at 
risk. Educational sessions for nursing staff 
were also implemented in 2012, and all cases 
of T1ROP were also discussed at the paediatric 
morbidity and mortality meetings from 2014.
Responsibility for selection for screen­
ing. In 2013, we decided to augment pae-
diatrician-based selection of infants with 
ophthalmologist selection.
Blenders and oxygen saturation moni­
tors. There was a shortage of blenders and 
saturation monitors, making oxygen supple-
mentation control impossible for most 
babies. In September 2013, new blenders 
and monitors were made available enabling 
better control of oxygen supplementation.
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Fig. 2. Numbers of infants screened, 2009 - 2014.
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Results
Infants screened (Fig. 2)
A total of 919 infants were screened and an 
additional 495 follow-up examinations were 
performed.
There was a progressive increase in the 
number of new referrals and in the total 
number of cases screened (new and follow-up 
cases combined) over the 6-year period, from 
33 to 292 and from 33 to 491, respectively.
The augmentation in 2013 of paedia-
trician-based selection of infants with 
ophthalmologist selection increased the 
annual number of new cases screened from 
195 in 2013 to 292 in 2014.
Infants screened late (after 6 weeks’ 
postnatal age)
All infants in 2009 were referred after 6 weeks’ 
postnatal age. No data were available for 2010 
- 2011. From 2012 onwards, the proportion of 
late referrals decreased from 51% to 33% in 
2013 and to 7.9% in 2014.
Cases of ROP detected
Fifteen infants had T1ROP and 223 T2 or 
earlier ROP. Of the screening failures, one 
infant had stage 4A disease in one eye and 
stage 5 in the other, and 5 other infants had 
bilateral stage 5 ROP on presentation.
Clinical findings and trends
Table 1 sets out proportions of patients with 
no ROP, T1ROP and T2 and earlier ROP. The 
incidence of T1ROP peaked in 2012 at 2.6% 
and decreased to 1.0% in 2014. T2 and earlier 
ROP peaked in 2013 at 30.3% and decreased 
to 24.0% in 2014. This decrease followed the 
introduction of new oxygen blenders and 
saturation monitors in September 2013.
Screening failures are set out in Table 2. 
All the bilaterally blind babies with stage 
5 ROP presented in the first year, when all 
the infants were examined late. The sixth 
infant who developed stage 5 ROP had 
aggressive posterior ROP and developed 
stable stage 4A ROP in the fellow eye after 
laser photocoagulation.
Management and outcome of 
T1ROP
Twelve infants underwent indirect laser 
photocoagulation and 3 had an intravitreal 
injection of bevacizumab. The latter treat-
ment was reserved for zone I disease.
Two patients in the laser group developed 
high myopia. The infant with aggressive poste-
rior ROP had bilateral laser photocoagulation, 
but developed stable stage 4A ROP in one eye 
and stage 5 ROP in the other.
The infants treated with bevacizumab 
injections did not have any adverse events 
and did not need further injections or laser 
photocoagulation. One of these patients 
was reviewed at 17 months of age and had 
persistent incomplete vascularisation of zone 
III but no recurrence of the ROP.
Additional ophthalmological 
problems
Additional ophthalmological problems found 
incidentally during ROP screening included:
• Bilateral dense cataracts in 3 patients
• Cytomegalovirus retinitis in 1 patient
• Congenital glaucoma in 2 patients
• Presumed rubella keratitis and retinal 
vasculitis in 1 patient
• Transient retinal haemorrhages in 6 
patients (no ROP).
Complications encountered  
during screening
Apnoea developed in two infants during 
examination. In both cases only mechanical 
(bag-valve-mask) ventilation was needed for 
less than a minute to resuscitate them, and 
there were no serious sequelae of these 
adverse events.
Discussion
The challenge of managing the increasing 
load of screening for ROP in middle-income 
countries with limited resources requires 
some unique solutions.
In our study, a large increase in the 
number of ROP examinations was achieved 
by: (i) having a dedicated ROP screening 
room and incubator; (ii) having enough 
ophthalmologists to ensure weekly screening; 
(iii) being involved in the paediatric 
department academic programme; and (iv) 
aiding the selection/referral process.
In 2014 the ratio of total to new examina-
tions was 491:292, which represents a mean 
of 1.7 examinations per infant. This number 
could be used for planning ROP screening in 
other hospitals offering similar care.
In the first year of screening, five patients 
with untreatable bilateral stage 5 ROP were 
found at the first examination. Subsequent 
to that, there was only one child who had 
aggressive posterior ROP who went on to 
develop stage 5 ROP in the right eye and stable 
stage 4A ROP in the left eye despite laser 
treatment. This highlights the importance of 
timeous screening for ROP, a disease with a 
very narrow window period for intervention.
Two major factors played a role in reducing 
the incidence of T1ROP from its peak at 2.6% 
to 1% by 2014. Initially there was a shortage 
of oxygen blenders and oxygen saturation 
monitors, making it impossible to monitor 
every baby adequately. The acquisition of 
more monitors and blenders, coupled with 
formal education on ROP, made targeted 
oxygen supplementation possible. Chow et 
al.[3] showed that a very strict oxygen therapy 
protocol can reduce the incidence of T1ROP, 
and although this is only achievable in well-
staffed and well-equipped hospitals, it should 
be something to strive for.
Thirteen patients with other ophthal-
mological problems were also detected at 
an early stage in the screening programme. 
Six patients (3 with bilateral cataracts, 1 
with cytomegalovirus retinitis and 2 with 
congenital glaucoma) needed surgical inter-
vention or antiviral therapy.
Study limitations
A weakness of our programme and of our 
study is the incomplete data in the first 3 
years. Accurate record keeping in the latter 
3 years helped to give a better understanding 
of how successful our screening programme 
was and how the improved paediatric care 
had decreased the incidence of ROP.
Conclusions
If we are to halt the ‘third epidemic’ of ROP 
in SA, we need to raise awareness of the 
disease in hospitals that have previously not 
been faced with the challenge of managing 
babies at risk, and implement and adhere 
to postnatal care protocols, in particular 
oxygen supplementation guidelines and 
ophthalmic screening protocols.
In this study we demonstrated the 
impor tance of a close working relationship 
Table 2. Screening failures (% of new 
cases screened)
Year Stage 4 Stage 5
2009 0 14.2
2010 0 0
2011 0 0
2012 0.5 0.5
2013 0 0
2014 0 0
Table 1. Clinical findings (% of new 
cases screened)
Year
No 
ROP
Type 2 and  
earlier ROP
Type 1 
ROP
2009 85.8 0 0
2010 86.0 13.6 0
2011 74.2 23.3 2.5
2012 68.5 28.3 2.6
2013 68.2 30.3 1.5
2014 75.0 24.0 1.0
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between ophthalmologists and paediatricians in setting up a new 
ROP programme.
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